Evidence map›Paper›PMID 41630535›Full record

ArticleClinical and translational science2026

Dicloxacillin and Flucloxacillin Inhibit Hepatic Uptake Transporters-In Vitro Investigations and Physiologically Based Pharmacokinetic Modeling.

Noora Sjöstedt, Ogochukwu U Amaeze, Jeroen J M W van den Heuvel, Tore B Stage, Jan B Koenderink, Nina Isoherranen, Heidi Kidron, Erkka Järvinen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Noora SjöstedtDivision of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.ORCID 0000-0001-6960-7757
Ogochukwu U AmaezeDepartment of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington, USA.ORCID 0000-0003-3348-7700
Jeroen J M W van den HeuvelDivision of Pharmacology and Toxicology, Department of Pharmacy, Radboud University Medical Center, Nijmegen, the Netherlands.
Tore B StageClinical Pharmacology, Pharmacy, and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark.ORCID 0000-0002-4698-4389
Jan B KoenderinkDivision of Pharmacology and Toxicology, Department of Pharmacy, Radboud University Medical Center, Nijmegen, the Netherlands.
Nina IsoherranenDepartment of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington, USA.ORCID 0000-0002-9548-3126
Heidi KidronDivision of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.ORCID 0000-0001-6427-8042
Erkka JärvinenDivision of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.ORCID 0000-0001-8970-5194

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dicloxacillin and flucloxacillin are β-lactamase-resistant penicillin antibiotics that have been in clinical use for over 50 years. While both antibiotics are known to induce cytochrome P450 enzymes, there is limited information available regarding their interactions with drug transporters. Here, we investigated the in vitro transport and inhibition of hepatic organic anion transporting polypeptides (OATPs) and renal organic anion transporters (OATs) by these antibiotics in recombinant transporter overexpressing HEK293 cells. We also investigated the transport of these antibiotics by efflux transporters, as well as their inhibition of breast cancer resistance protein (BCRP) and P-glycoprotein (P-gp) using a HEK293 membrane vesicle transport assay. Dicloxacillin and flucloxacillin inhibited rosuvastatin transport by OATP1B1, OATP1B3, and OATP2B1, and the inhibition was strongest for OATP1Bs with IC

Indexed as

Anti-Bacterial AgentsDicloxacillinFloxacillinLiverOrganic Anion TransportersATP Binding Cassette Transporter, Subfamily G, Member 2Biological TransportDrug InteractionsHEK293 CellsHumansLiver-Specific Organic Anion Transporter 1Models, BiologicalNeoplasm ProteinsRosuvastatin CalciumSolute Carrier Organic Anion Transporter Family Member 1B3ABCG2 protein, humanAnti-Bacterial AgentsATP Binding Cassette Transporter, Subfamily G, Member 2DicloxacillinFloxacillinLiver-Specific Organic Anion Transporter 1Neoplasm ProteinsOrganic Anion TransportersRosuvastatin CalciumSLCO1B1 protein, humanSLCO1B3 protein, humanSLCO2B1 protein, humanSolute Carrier Organic Anion Transporter Family Member 1B3antibioticsDDIdrug–drug interactioninhibitionin silicoin vitroPBPKtransporter

Identifiers

PMID41630535
PMCPMC12865225

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.